Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming.

Oncogene - 2 Mar 2017

Romero O A, Verdura S, Torres-Diz M, Gomez A, Moran S, Condom E, Esteller M, Villanueva A, Sanchez-Cespedes M

Abstract excerpt

Components of the SWI/SNF chromatin remodeling complex, including BRG1 (also SMARCA4), are inactivated in cancer. Among other functions, SWI/SNF orchestrates the response to retinoid acid (RA) and glucocorticoids (GC) involving downregulation of MYC. The epigenetic drugs SAHA and azacytidine, as well as RA and GC, are currently being used to treat some malignancies but their therapeutic potential in lung cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucocorticoids

Share to Histone Deacetylase Inhibitors

Share to Hydroxamic Acids

Share to Proto-Oncogene Proteins c-myc

Share to Tretinoin

Share to Vorinostat

Source

Identifiers

PMID: 27593925
DOI: 10.1038/onc.2016.296

Genes

MYC
SMARCA4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming.PMID 27593925Read ↗

The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer.Semantic proximity Read ↗

Retinoic Acid affects Lung Adenocarcinoma growth by inducing differentiation via GATA6 activation and EGFR and Wnt inhibitionSemantic proximity Read ↗

Intersection of retinoblastoma tumor suppressor function, stem cells, metabolism, and inflammationSemantic proximity Read ↗

Inhibition of MYC attenuates tumor cell self‐renewal and promotes senescence in SMARCB1‐deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivoSemantic proximity Read ↗

Targeting of BRM Sensitizes BRG1 -Mutant Lung Cancer Cell Lines to RadiotherapySemantic proximity Read ↗

Therapeutically targeting oncogenic CRCs facilitates induced differentiation of NB by RA and the BET bromodomain inhibitorSemantic proximity Read ↗

Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancersSemantic proximity Read ↗

BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR DependencySemantic proximity Read ↗

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockadeSemantic proximity Read ↗

EZH2/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4/ERK/c-Myc signaling axisSemantic proximity Read ↗

A Novel Histone Deacetylase Inhibitor Exhibits Antitumor Activity via Apoptosis Induction, F-Actin Disruption and Gene Acetylation in Lung CancerSemantic proximity Read ↗

The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.